
Melissa Lechner MD PhD
Diabetes, Lipid Metabolism, Thyroid
Assistant Professor of Medicine
Join to View Full Profile
10833 LeConte Ave, 57-145Los Angeles, CA 90095
Phone+1 310-794-7555
Fax+1 310-794-7555
Dr. Lechner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Melissa G. Lechner, MD, PhD is an Assistant Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at the UCLA David Geffen School of Medicine. Her clinical and research interests are related to endocrine disease resulting from cancer immunotherapy (onco-endocrinology) and advanced thyroid cancer. She established the Onco-Endocrinology clinic at UCLA to care for patients with endocrine side effects from cancer immunotherapy and targeted therapies. She also has expertise in thyroid nodules (including biopsy).
Dr. Lechner leads multiple prospective clinical trials at UCLA studying thyroid disease and cancer immunotherapy. She has received funding from the American Thyroid Association, Endocrine Fellows Foundation, and National Institutes of Health for her research and has been invited to speak nationally and internationally on the role of the immune system in cancer. She has published articles in Thyroid, The Journal of Clinical Endocrinology and Metabolism, The Journal of Immunology, Cancer, and Clinical Cancer Research, including original research and invited reviews, and serves on the National Comprehensive Cancer Network of Management of Immunotherapy Toxicity Side Effects guidance panel.
After finishing her combined MD and PhD training in the joint USC Keck School of Medicine/Cal Tech physician-scientist training program, Dr. Lechner completed residencies in internal medicine and pediatrics at Brigham and Women's Hospital and Boston Children's Hospital of the Harvard Medical School. In 2018, she joined UCLA as a clinical fellow in endocrinology and post-doctoral researcher in the prestigious Specialty Training and Advanced Research (STAR) program. In 2020, Dr. Lechner joined the faculty at UCLA.
Clinical Expertise
- Thyroid disease, Basic Science Research, Clinical and translational research, Onco-Endocrinology, Thyroiditis, Thyroid nodules and thyroid cancer, Immune toxicities of cancer immunotherapy
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2018 - 2020
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2015 - 2018
Keck School of Medicine of the University of Southern CaliforniaClass of 2014
Certifications & Licensure
CA State Medical License 2018 - 2026
MA State Medical License 2017 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.Ling Zhu, Yee-Ming M Cheung, Cherie Chiang, Emily J Gallagher, Ole-Petter R Hamnvik
Journal for Immunotherapy of Cancer. 2025-10-15 - Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy.Nicole L Huang, Jessica G Ortega, Kyleigh Kimbrell, Joah Lee, Lauren N Scott
JCI Insight. 2025-07-08 - Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer.Alexis LeVee, Esther Peluso, Melissa G Lechner, Nora Ruel, Joanne Mortimer
The Oncologist. 2025-06-04
Press Mentions
Common Autoimmune Drug May Help Reverse Immunotherapy-Induced Diabetes, UCLA Study FindsOctober 29th, 2025
Breakthrough Drug Could Prevent Deadly Side Effect of Cancer TreatmentJuly 10th, 2025
HMN 2025: How Common Autoimmune Drug Could Assist Reverse Immunotherapy-Induced DiabetesJuly 9th, 2025- Join now to see all
Grant Support
- Targets for Prevention of Autoimmune Toxicities from Checkpoint ImmunotherapyAramont Charitable FoundationPresent
- Mechanisms of Thyroid Autoimmunity in Checkpoint ImmunotherapyNational Institutes of Health (NIDDK)Present
- Role of Recent Thymic T Cells in Immune Checkpoint Inhibitor ThyroiditisAmerican Thyroid AssociationPresent
Professional Memberships
- Member
- National Comprehensive Cancer NetworkMember
External Links
- Research Grouphttps://maureensulab.wixsite.com/maureensugroup
- Pubmed Bibliographyhttps://www.ncbi.nlm.nih.gov/myncbi/melissa.lechner.1/bibliography/public/
- ATA Researchhttps://www.thyroid.org/professionals/research-grants/thyroid-research-recipients-2020/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









